

Jennifer Arnold, MD, PhD Assistant Professor of Neurology SIU School of Medicine April 4, 2024



DALE & DEBORAH SMITH CENTER
FOR ALZHEIMER'S RESEARCH
& TREATMENT

Outline



- Introduction
- Definitions
- Causes of cognitive impairment and dementia
- Current management of dementia
- Conclusions

Introduction



- 10% of Americans age 45 and older report subjective cognitive decline
 - But 54% of these people have not sought evaluation for this
- After 65, risk of cognitive impairment increases
 - 1 in 9 people >65 has Alzheimer's disease in the US
- Incidence rate of AD is decreasing (new cases per year)
 - Likely due to improvement in risk factors, especially vascular
- Total number of cases continues to rise, however
 - Impact of COVID-19 unknown but likely will contribute

Definitions



 Memory changes, trouble with memory, cognitive changes, etc – subjective trouble with memory or other cognitive tasks

- Mild cognitive impairment
 - Subjective complaints of cognitive changes and objective measure of cognitive impairment, but not overtly affecting daily function

Dementia

- Non-reversible process causing deterioration in cognition beyond what is expected in normal biological aging that interferes with daily living
- What does "interferes with daily living" mean?

Is it dementia?



- Medications
 - Benzos
 - Opioids
 - Hypnotics
 - Anticholinergics
 - Barbiturates
 - Seizure meds, muscle relaxers
 - Antipsychotics
- Other medical issues, deficiencies, toxicities
 - Vitamin deficiencies B12, B1, folate
 - Endocrine dysfunction thyroid
 - Chronic liver or kidney disease
 - Severe lung disease, heart failure
 - Inflammatory/autoimmune disease
 - Infections

- Sleep disruption
 - Obstructive sleep apnea
 - Insomnia
- Depression, anxiety
- Other neurological causes
 - Longstanding MS
 - Epilepsy or seizures
 - Traumatic brain injury
 - Stroke
 - Tumors or other masses
- Pain
- Hearing and/or vision loss

Workup for cognitive impairment



- History
- Screen for sleep apnea
- Screen for depression, anxiety
- Physical exam
- Cognitive screening tests
 - MMSE
 - MoCA
 - SLUMs

- Basic labs
 - CBC
 - Metabolic panel
 - Thyroid function
 - B12, other vitamins
- Imaging
 - CT
 - MRI
- Neuropsychological testing

Causes for dementia




- Alzheimer's disease
- Vascular dementia
- Dementia with Lewy bodies and Parkinson's disease dementia
- Frontotemporal dementia
- Less common PSP, Huntington's disease, CTE, LATE


Alzheimer's disease



- Most common cause of dementia in the US and in the world
- Estimated prevalence of 6.5 million people over age 65 living with AD in the United States
 - 1/9 people over 65
 - 73% of these people are over age 75
- Due to accumulation of amyloid-beta plaques & neurofibrillary tangles of p-tau



Perl D. Mt Sinai J Med 2010; 77:32



Keene CD et al. UptoDate 2023





- Short term episodic memory loss
 - Forgetting recent events, conversations, asking repetitive questions
 - Misplacing objects, forgetting to pay bills or take medications
- Executive dysfunction
 - Difficulty making decisions, multitasking
 - Driving
 - Difficulty with finances and taxes
- Difficulty completing familiar tasks
 - Hobbies
 - Household chores, cooking
 - Using technology and utilities

- Visual and spatial relationship difficulties
 - Getting lost driving in familiar places
 - Wandering
- Language difficulties
 - Word finding
- Changes in judgement, behavior, personality
 - Decision making, basic ADLs
 - Leaving the stove on, car running
 - Financial decisions
 - Worsening irritability or mood lability
 - Aggressive behaviors
 - Delusions and hallucinations

Alzheimer's disease diagnosis




Normal neurological exam


Cognitive testing – memory predominant deficits

• MRI/CT with atrophy especially mesial temporal and parietal

Healthy control



Alzheimer's disease



Ledig et al. Scientific Reports 2018; 8:11258


Alzheimer's disease biomarkers



- Spinal fluid and serum amyloid and tau levels decreased A-beta42, increased total and p-tau
 - Ratios often used P-tau/Abeta42 or Abeta42/40 ratios
 - CSF testing Athena ADmark®
 - Serum testing PrecivityAD®



- PET scan
 - Amyloid/tau shows accumulation of tracer
 - Medicare coverage!



Vascular dementia




- Cognitive impairment due to vascular brain injury
 - Ischemic stroke, hemorrhage, microvascular disease
- Second most common dementia type 15-20% of diagnosed patients
- Two main types:
 - Slowly progressive over time due to microvascular disease "Binswanger's disease"
 - Stepwise worsening of cognition due to new strokes over time multi-infarct dementia
 - (Post-stroke)
- Risk factors cardiovascular
 - Hypertension
 - Hyperlipidemia
 - T2 diabetes

- Smoking
- Atrial fibrillation
- Coronary artery disease

Vascular dementia




Microvascular disease




Case courtesy of Frank Gaillard, Radiopaedia.org, rID: 10674

Intracerebral hemorrhage



Case courtesy of Charlie Chia-Tsong Hsu, Radiopaedia.org, rID: 19872

Microhemorrhages



Suppiah et al. *Diagnostics* (Basel) 2019; 9:65

Dementia with Lewy bodies and Parkinson's disease dementia



- Due to accumulation of α -synuclein Lewy bodies = Lewy body
 - dementia (LBD)
- Exist on a spectrum relating to timing of symptoms



https://www.alz.org

Parkinson's disease

Dementia with Lewy bodies








- Cognitive impairment/dementia
 - Executive dysfunction
 - Trouble with attention
 - Bradyphrenia and slowed processing
 - Visuospatial difficulties
- Visual hallucinations
- Prominent fluctuations in cognition esp in DLB
- REM sleep behavior disorder
- Parkinsonism bradykinesia, resting tremor, postural instability, rigidity

Lewy body dementia diagnosis




- History and physical exam critical
- No biomarker scans or labs... yet
- DaT scan positive especially if parkinsonism present
 - Not specific to dementia
 - Usually not needed
- Syn-One Test® detects α-synuclein
 - Not clearly specific to disease
 - Insurance coverage unclear

Image courtesy of the American Parkinson Disease Association https://www.apdaparkinson.org



"Comma"-shaped Possible essential tremor



"Period"-shaped Possible parkinsonian syndrome





- Most common cause of early onset dementia before age 65
- Multiple causative processes, leading to frontal and/or temporal lobe predominant degeneration
 - "tauopathies" p-tau but different isoform than that in AD
 - TDP-43, ubiquitin
- Three main subtypes
 - Semantic primary progressive aphasia (svFTD)
 - Nonfluent agrammatic primary progressive aphasia (nfvFTD)
 - Behavioral variant frontotemporal dementia (bvFTD)






- Progressive deterioration of behavior
 - Disinhibition
 - Apathy
 - Loss of empathy/sympathy
 - Oral fixations and dietary changes
 - Perseverative or ritualistic behavior
 - Cognitive testing executive dysfunction, sparing of memory and visuospatial tasks
- This is not anxiety, psychosis, depression





ALE & DEBORAH SMITH CENTER FOR ALZHEIMER'S RESEARCH & TREATMENT



From Boeve B. Continuum 2022; 28:702

Primary progressive aphasia



- Loss of language functions
- Semantic variant most rare
 - Loss of knowledge of words
 - Fluent, no issues with grammar
- Nonfluent, agrammatic variant
 - Loss of speech production, fluency
 - Agrammatism
 - Knowledge of words spared

- Logopenic variant
 - Usually due to Alzheimer's pathology
 - Word finding difficulties
 - Cannot repeat even simple phrases
 - Make errors saying "blant" for "plant"
 - Fluent, no issues with grammar
 - Circumlocution talking around a subject, unable to get to the specific word or sentence





- No biomarker PET scans tau-PET not useful, no ligands from other proteins
- No serum studies
 - May be able to eventually distinguish AD from FTD if amyloid or p-tau markers are found
- No CSF markers
 - Similar to serum, may be useful to distinguish AD biomarkers in patients with unclear diagnosis
- Neuropsychological testing may miss symptoms
 - Attention/concentration, executive function, language can also be affected in other neurodegenerative diseases and non-neurodegenerative diseases





- Progressive supranuclear palsy –
 PSP
 - Mostly due to tau accumulation
 - Axial parkinsonism with frequent falls, very slow and flat (akinesia), spastic speech and swallowing issues, vertical gaze restrictions
 - 70% of PSP patients will develop dementia
 - Executive dysfunction, apathy, language problems (esp nfPPA)

- LATE Limbic-predominant Agerelated TDP-43 Encephalopathy
 - In the oldest old (>85 years)
 - Due to accumulation of TDP-43, especially in the anterior hippocampus
 - Slower than AD, with memory loss only
 - Still being characterized

Summary of most common types of dementia



	Alzheimer's disease	Vascular dementia	Lewy body dementia	Frontotemporal dementia
Typical age	Age >65, increases with age	Age >65	Average age of onset 75	Age 45-65, more likely genetic
Typical symptoms	 Short term memory loss Executive dysfunction, trouble with daily tasks Later, agitation, delusions 	 Symptoms related to location of injury – language, visuospatial, motor skills Often executive dysfunction 	 Dementia – executive dysfunction, visuospatial issues, slowed thought processes REM sleep behavior disorder, fluctuations, visual hallucinations Parkinsonsim – slowed movements, rigidity, resting tremor, gait instability 	Behavioral changes – disinhibition, loss of empathy, dietary changes/hyperorality, language problems
Brain changes	 Due to amyloid plaques and tau tangles Atrophy in the temporal lobe (hippocampus) and pariental lobe 	Due to vascular injuries – ischemia, hemorrhage	 Due to Lewy bodies (aggregates of α-synuclein) in the cortex Atrophy more generalized in the cortex 	 Due to accumulation of proteins, most commonly tau or TDP43 Atrophy in the frontal and/or temporal lobe
Treatment	 Treat with cholinesterase inhibitors, memantine Anti-amyloid antibodies available 	 Prevent worsening by vascular risk factor reduction Cholinesteraase inhibitors may be helpful 	 Cholinesterase inhibitors (may also improve fluctuations and hallucinations) Carbidopa-levodopa for motor (parkinsonian) symptoms 	 Cholinesterase inhibitors and memantine not indicated, may worsen behavior Some evidence for SSRIs





- Many patients will come in with reported "memory" problems
 - A lot of these are not truly memory executive dysfunction, language, attention
- Comorbidities vary
- Risks and genetics vary
- Diagnostic clarity for patients and families
- Treatments vary

Treatment of dementia



- Pharmacologic of disease
 - Symptomatic
 - Disease modifying therapy
- Other pharmacologic
 - Treating mood, anxiety, behavior
 - Sleep, other symptoms
- Non-pharmacologic
 - Education
 - Assistance
 - Behavior modification






Treatment of dementia



- Pharmacologic
 - Symptomatic
 - Disease modifying therapy
 - Anti-amyloid antibodies currently FDA approved
 - Many trials for other proteins, none have made it through







Disease-modifying therapy

Treatment of dementia



Pharmacologic - symptomatic

- Cholinesterase inhibitors
 - FDA approved for Alzheimer's disease
 - Rivastigmine also approved for PD dementia
 - Used for PDD and DLB, also for amnestic MCI
 - May improve symptoms in vascular dementia
 - No benefit in FTD
- Memantine –NMDA antagonist
 - FDA approved for mod-severe AD only
 - Not clearly helpful in PDD or DLB
 - No benefit in FTD, may worsen function and symptoms

Donepezil



Rivastigmine



Galantamine





Treating other symptoms



- Depression and anxiety
- SSRIs sertraline, fluoxetine, citalopram, etc
- SNRIs, bupropion, mirtazapine
- Avoid benzos, tricyclics
- SSRIs and trazodone may improve behavior in FTD patients

- Motor symptoms in parkinsonism
 - Dopamine replacement
 - Carbidopa-levodopa
 - Dopamine agonists
 - COMT, MAOB inhibitors
 - Anticholinergics amantadine, Artane
 - Avoid in cognitively impaired
- Autonomic dysfunction
 - Orthostatic hypotension
 - Constipation
 - Urinary frequency/urgency

Treating other symptoms



- Sleep apnea
- Insomnia
 - Melatonin
 - Mirtazapine
 - Trazodone
 - Ambien/others not great
 - AVOID TCAs, antihistamines, benzos, antipsychotics
- Vascular risk factor reduction also important for Alzheimer's and other dementias and overall brain health








- Prevention of dementia focusing on improving modifiable risks
- Improve cardiovascular health
- Exercise, maintain cognitive and social activity
- Avoid smoking, illicit drugs, limit alcohol
- Improve sleep





Non-pharmacologic treatments

SIU MEDICINE

FOR ALZHEIMER'S RESEARCI

- Improving behaviors and Coping
 - Communication
 - Review photos, souvenirs, reminisce
 - Organization and routine
 - Home safety
 - Validate feelings
 - Find meaningful activities and interests
 - Senior centers and day centers
 - Music and Art Beyond the Medical Center
 - Limit expectations







- Cognitive impairment and dementia is a common problem in the aging population, and is going to get worse
- There are many causes of cognitive impairment, some of which are reversible
- The most common types of dementia are Alzheimer's disease, vascular dementia, dementia with Lewy bodies, and frontotemporal dementia
- Pharmacologic treatment of the specific disease varies but management of these problems is much more than medication and patients benefit from a multidisciplinary approach

Thank you!

